Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation

by Anna Vassall, Mariana Siapka, Nicola Foster et al.
The Lancet Global Health, Vol. 5, No. 7, e710–e719, July 2017

10 pp. 2.0 MB
http://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(17)30205-X.pdf

In 2010 a new diagnostic test for tuberculosis, Xpert MTB/RIF, received a conditional programmatic recommendation from WHO. Several model-based economic evaluations predicted that Xpert would be cost-effective across sub-Saharan Africa. The authors investigated the cost-effectiveness of Xpert in the real world during national roll-out in South Africa. They we found that Xpert introduction in South Africa was cost-neutral, but found no evidence that Xpert improved the cost-effectiveness of tuberculosis diagnosis. Their study highlights the importance of considering implementation constraints, when predicting and evaluating the cost-effectiveness of new tuberculosis diagnostics in South Africa.

(Visited 9 times, 1 visits today)
This entry was posted in General, Tuberculosis. Bookmark the permalink.